

Functional comparison of *Clostridium butyricum* and sodium butyrate supplementation on growth, intestinal health, and the anti-inflammatory response of broilers

Ling Liu

Huazhong Agricultural University

Huayun Ling

Wuhan SunHY Biology Co.,Ltd

Wei Zhang

Wuhan SunHY Biology Co.,Ltd

Ying Zhou

Wuhan SunHY Biology Co.,Ltd

Youguo Li

Huazhong Agricultural University

Nan Peng

Huazhong Agricultural University

Shumiao Zhao (✉ shumiaozhao@mail.hzau.edu.cn)

Huazhong Agricultural University

Research

Keywords: *Clostridium butyricum*, sodium butyrate, broiler, growth performance, intestinal health, anti-inflammatory response

Posted Date: October 12th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-955295/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Functional comparison of *Clostridium butyricum* and sodium butyrate**
2 **supplementation on growth, intestinal health, and the anti-inflammatory**
3 **response of broilers**

4
5 Ling Liu^{1#}, Huayun Ling^{1,2#}, Wei Zhang², Ying Zhou², Youguo Li¹, Nan Peng¹,
6 Shumiao Zhao^{1*}

7
8 ¹ State Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory,
9 College of Life Science and Technology, Huazhong Agricultural University, Wuhan,
10 430070, Hubei, P.R. China

11 ²Wuhan SunHY Biology Co.,Ltd, Wuhan, 430206, P.R. China

12

13 *To whom correspondence should be addressed.

14 Tel: +86 27 8728 1040, Fax: +86 27 8728 0670,

15 Email: shumiaozhao@mail.hzau.edu.cn

16

17

18 # These authors contributed equally to this work.

19 **Abstract**

20 **Background:** Butyrate has been reported to promote proliferation of colonic
21 epithelial cells and maintain intestinal barrier integrity in broilers. Although
22 supplementation of *Clostridium butyricum* and sodium butyrate have been shown to
23 confer benefits on broilers, their effects and mechanisms have not been compared.

24 **Results:** In this study, *C. butyricum* and sodium butyrate were added into the basal
25 diet of broilers and their effects on growth performance, intestinal health, and anti-
26 inflammatory response were analyzed. It was found that both *C. butyricum* and
27 sodium butyrate showed good probiotic effects on broilers. Their effects on growth
28 rate and expression of inflammation related genes were even superior to that of
29 antibiotic. Besides, the two dietary supplements improved intestinal structure integrity
30 and secretion of inflammatory cytokines, although the antibiotic had negative effects.
31 Comparison of the two supplements revealed that sodium butyrate more effectively
32 improved the growth and intestinal structure of broilers than *C. butyricum*. On the
33 contrary, *C. butyricum* was superior to sodium butyrate in promoting tight junction
34 protein expression, SCFAs production, and anti-inflammatory response.

35 **Conclusions:** In summary, this study demonstrates the positive effects of *C.*
36 *butyricum* and sodium butyrate on broilers, and will serve as a reference for selection
37 of appropriate butyrate supplementation for broilers in the breeding industry.

38

39

40 **Keywords:** *Clostridium butyricum*; sodium butyrate; broiler; growth performance;

41 intestinal health; anti-inflammatory response

42 **Background**

43 Short-chain fatty acids (SCFAs), a class of organic acids that includes acetate,
44 propionate, and butyrate, are important metabolites produced by intestinal microbial
45 anaerobic fermentation (1). Numerous studies currently show that SCFAs exert
46 diverse functions on the host (2). SCFAs, for example, contribute to the integrity of
47 the gut structure by meeting a significant portion of the energy requirements of
48 colonic epithelial cells (3). Additionally, SCFAs promote intestine health in a variety
49 of other ways, including phagocytosis, intestinal dynamic balance, and immune
50 regulation (4). Butyrate, a typical C₄ SCFA, has garnered much attention in recent
51 years for its beneficial effects on intestinal health (5). Butyrate is the most important
52 energy substance of colon cells, promoting epithelial cell growth and differentiation
53 (6, 7). Some studies have also shown that butyrate, as an anti-inflammatory agent,
54 plays an essential role in modulating immune response and intestinal barrier function
55 (4, 8).

56 Because of its positive effects on the host, including butyric acid into dairy diets
57 to promote animal growth has become a widely adopted strategy in the feeding
58 industry (9, 10). There are different approaches for increasing the amount of butyric
59 acid in the diet, including dietary fiber, butyrate, and butyrate-producing bacteria.
60 *Clostridium butyricum* spores and sodium butyrate are the two most common butyric
61 acid supplements in the market. *C. butyricum*, a butyric acid-producing anaerobic
62 bacterium, is widely distributed in animal guts and the natural environment (11). Due
63 to its beneficial properties, *C. butyricum* has been recognized as a typical probiotic on

64 a global scale. *C. butyricum* has been shown in previous research to significantly
65 improve broiler growth performance, nutritional metabolism, intestinal morphology,
66 and intestinal immune dynamic balance (12-14). Additionally, it enhances intestinal
67 barrier function and inhibits the inflammasome signaling pathways in weaned piglets
68 challenged with enterotoxigenic *Escherichia coli* K88 (15). Numerous studies have
69 reported that sodium butyrate, the sodium salt of butyric acid, has positive effects on
70 growth performance and intestinal integrity in piglets and broiler chickens when used
71 as a feed supplement (16-18). Additionally, it has been shown to repair the
72 imbalanced gut flora caused by a high-fat diet in mice (19).

73 Although the effects of *C. butyricum* and sodium butyrate on broiler's growth
74 performance and intestinal health have been extensively investigated, the similarities
75 and differences in their probiotic function remain unknown. In this study, we
76 investigated the impact of *C. butyricum* and sodium butyrate on broilers. Our findings
77 indicated that both had varying degrees of positive effects on broilers and comparing
78 their functional differences may help guide market selection of butyric acid
79 supplements.

80

81 **Methods**

82 *Experimental design*

83 A total of 360 one-day-old Cobb500 broilers were randomly assigned to four groups
84 with each group consisting of 15 birds and 6 replicates for each group (Table 1).

85 These four groups were set as follows: basal diet (Control) and a basal diet

86 supplemented with 100 g/t (1.0×10^9 CFU/g) *C. butyricum* spores (CB), 500 g/t
87 sodium butyrate (SB), or 200 g/t oxytetracycline (Antibiotic), respectively. [Table 2](#)
88 summarizes the composition and nutritional content of the basal diet. *C. butyricum* and
89 SB were obtained from Wuhan SunHY Biology Co., Ltd.

90 Broilers were raised in wire cages with sufficient ventilation and water supply,
91 and the room temperature was maintained between 22-25°C. Before the experiment,
92 the equipment was cleaned and disinfected, particularly, it was fumigated with
93 potassium permanganate and formaldehyde after cleaning and drying. Immunization
94 and deworming procedures were conducted concurrently with the farm routine.
95 Continuous feeding three times daily at a set time was conducted. Throughout the trial
96 period, the feeding and health of broilers were monitored and documented. The
97 breeding experiment was conducted at SunHY Biology Co., Ltd's Huanghu breeding
98 facility.

99

100 ***Sample collection***

101 Before the experiment started, twelve broilers (two from each replicate) were selected
102 at random from each group to be weighed. The feeding of an additional twelve
103 broilers (selected as above) was stopped at 9:00 p.m. on the 21st and 42nd days of the
104 experiment, respectively, and their water supply was stopped at 7:00 a.m. on the 22nd
105 and 43rd days. The body weight was recorded, they were killed, and the abdominal
106 cavity was rapidly opened to separate jejunum, ileum, and cecum. Samples of the
107 jejunum, ileum, and cecum (about 1-2 cm from the midpoint) were fixed in 4%

108 paraformaldehyde for tissue section preparation and examination of intestinal
109 morphology. The jejunum was cut, washed with sterile normal saline, scraped, and
110 frozen at -80°C for DNA extraction and gene expression analysis. Ileum and cecal
111 chyme were collected and stored at -20°C for subsequent analysis of volatile SCFAs.
112 Meanwhile, cecum digested samples were taken out and stored at -80°C for 16s rDNA
113 high-throughput sequencing.

114

115 ***Growth performance measurement***

116 Throughout the study, the daily feed consumption, body weight, and health of the
117 broilers were all documented. The following formula was used to determine feed
118 intake (FI), body weight gain (BWG), and feed to gain ratio (F/G).

119
$$FI \text{ (g/d}\cdot\text{bird)} = \sum [(\text{Feed amount} - \text{Residual amount}) / \text{Number of broilers}] /$$

120 Days.

121
$$BWG \text{ (kg/d}\cdot\text{bird)} = (\text{Final average weight} - \text{Initial average weight}) / \text{Days}.$$

122
$$F/G = \text{Total feed consumption} / \text{Total weight gain}.$$

123

124 ***Analysis of intestinal histomorphology***

125 Jejunum, ileum, and cecum segments were fixed in formaldehyde and embedded in
126 paraffin. Consecutive sections (5 mm) were stained with eosin-methylene blue for
127 morphological observations using an optical microscope. From each section, fifteen
128 villi were randomly selected and their villi height (V) and crypt depth (C) were
129 measured. Villus height refers to the distance from the apex of the villus to the

130 entrance of the crypt, while crypt depth refers to the distance between the base of the
131 villus and the basal mucosa. The following formula was used to determine the villi
132 height to crypt depth ratio (V/C).

$$133 \quad V/C = \text{Villi height} / \text{Crypt depth.}$$

134

135 ***16S rDNA sequencing***

136 The variable region V3 of the cecal microflora 16s rDNA gene was sequenced using
137 454 high-throughput sequencing technology. The software (Mothur) was used to
138 remove the low-quality DNA sequences, and then the distance between the sequences
139 was calculated. Operational taxonomic units (OTUs) were determined as filtered
140 sequencing clusters with a 97% similarity level. The microbial diversity of various
141 treatments was investigated and compared using the Sliva and RPD databases. Sangon
142 Biotech (Shanghai) Co., Ltd performed the sequencing.

143

144 ***Determination of SCFAs concentrations***

145 Gas chromatography-mass spectrometry (GC-MS) was used to determine the
146 concentrations of standard solutions and volatile SCFAs in the ileum and cecum
147 chyme. Acetic acid, propionic acid, or butyric acid were dissolved in ether to form
148 standard solutions of varying concentrations. 50 mg of chyme was dissolved in a
149 mixture of 50 μ L phosphoric acid (15%), 100 μ L isohexanoic acid (125 μ g/mL), and
150 400 μ L ether. The sample was then vortexed and centrifuged at 13,000 g for 10 min at
151 4°C. For analysis, the supernatant was injected into the chromatographic column.

152 SCFAs were analyzed using a Thermo TRACE 1310-ISQ GC-MS system, equipped
153 with an Agilent HP-INNOWAX column (30 m × 0.25 mm ID × 0.25 μm). The split
154 injection was carried out using a 1 μL injection volume (split ratio 10:1). The inlet and
155 transmission line temperature was 250°C, the ion source temperature was 230°C, and
156 the quadrupole temperature was 150°C. The carrier phase was helium at a flow rate of
157 1.0 mL/min. MS was carried out using an electron bombardment ionization (EI)
158 source and SIM scanning mode. The electron energy was 70 eV.

159

160 *Expression of intestinal inflammatory factors and tight junction protein genes*

161 RNA from the jejunum samples was extracted, and cDNA was obtained by reverse
162 transcription from total RNA. Occludin, ZO-1, TAK1, NF-κB, IL-1β, IL-6, and TNF-
163 α gene expression levels were then determined by real-time PCR. β-actin expression
164 gene was used as the reference gene. [Table 3](#) lists all of the primers used.

165

166 *Statistical analysis*

167 SPSS 16.0 (SPSS Inc., Chicago, IL, USA) was used for variance analysis, and
168 Duncan was used for multiple comparisons. The data were expressed as mean ± SD. p
169 < 0.05 was considered to be statistically significant.

170

171 **Results**

172 *Sodium butyrate promotes growth performance more effectively than C.*

173 *butyricum*

174 The feed to gain ratio (F/G) of four diets (Control, CB, SB, Antibiotic, [Table 1](#))
175 was maintained at 1.42-1.47 over 1-21 d ([Table 4](#)). However, when the feed
176 additive (*C. butyricum*, sodium butyrate, or oxytetracycline) was introduced, the
177 value significantly decreased ($p < 0.05$) from 2.05 to 1.90-1.92 during 22-42 d and
178 from 1.86 to 1.74-1.75 during 1-42 d ([Table 4](#)). Specifically, the SB group's body
179 weight gain (BWG) significantly increased ($p < 0.05$) from 56.31 g to 62.16 g over
180 the 22-42 d period and from 42.13 g to 45.76 g throughout the overall period (1-
181 42 d), while feed intake (FI) remained constant in the Control group ([Table 4](#)).
182 Although *C. butyricum* supplementation did not affect BWG in the CB group, FI
183 was significantly decreased ($p < 0.05$) from 115.68 g to 106.57 g during 22-42 d
184 and from 78.38 g to 73.73 g during 1-42 d ([Table 4](#)). Besides, there were no
185 significant differences ($p > 0.05$) in BWG and FI between the Antibiotic group and
186 the other two groups (CB, SB), respectively ([Table 4](#)). When compared to the CB
187 group, the addition of sodium butyrate significantly increased BWG and FI ($p <$
188 0.05) throughout 22-42 d and the overall period (1-42 d), but there were no
189 discernable changes in F/G ($p > 0.05$, [Table 4](#)).

190

191 ***C. butyricum and sodium butyrate improves intestinal health***

192 Antibiotic supplementation had a negative effect on virtually all indices of intestinal
193 structural integrity, including villus height (V), crypt depth (C), and the ratio of villi
194 height to crypt depth (V/C) ([Fig. 1](#) and [Table 5](#)), as well as damaged intestinal
195 morphology ([Fig. 1](#)). Broilers fed with diets supplemented with CB or SB, however,

196 had longer, wider villi (Fig. 1 and Table 5), and more goblet cells (Fig. 1). After 21
197 days, V and V/C of the jejunum and cecum in the CB and SB groups were both
198 significantly increased ($p < 0.05$) than in the non-supplemented Control group (Fig. 1
199 and Table 5). Specifically, V of jejunum samples was increased from 711.73 μm to
200 987.79 μm and 985.14 μm , respectively, while that of cecum increased from 143.95
201 μm to 166.58 μm and 187.70 μm at the same time (Table 5). V/C levels increased
202 from 4.88 to 7.62 and 8.41 in the jejunum, and from 1.13 to 1.45 and 1.74 in cecum
203 samples from two supplemented diets (CB, SB, Table 5). Furthermore, V/C of the
204 ileum was increased from 4.07 to 6.70 and 7.08, with significant statistical differences
205 ($p < 0.05$), and C was reduced from 127.23 μm to 76.58 μm in the CB group and
206 100.37 μm in the SB group ($p < 0.05$, Table 5). At 42 d, we observed that the V/C of
207 the jejunum, ileum, and cecum were almost all significantly increased ($p < 0.05$) in
208 the CB and SB diets (Table 5). In particular, the V/C of the jejunum increased from
209 5.43 to 6.93 in the SB group, that of the ileum increased from 5.39 μm to 6.58 μm and
210 6.73 μm , while that of the cecum samples increased from 0.93 to 1.50 and 1.75 (Table
211 5). Furthermore, it was clear that V/C in the SB group increased more apparent than
212 in the CB group, not only in various segments of the small intestine but also
213 throughout different development stages of broilers (Table 5).

214 Real-time PCR findings revealed that broilers fed the SB diet had higher levels
215 of Occludin gene expression ($p < 0.05$) than those in the Control group at all stages
216 (Fig. 2). Furthermore, *C. butyricum* supplementation significantly increased both
217 Occludin and ZO-1 expression ($p < 0.05$) at 42 d (Fig. 2). Specifically, the expression

218 level increased by 2.56 and 2.64, respectively (Fig. 2). However, all tight junction
219 protein genes were lowly expressed in the antibiotic-supplemented group, with
220 Occludin levels falling by 1.34-1.96, and ZO-1 levels falling by 1.35-1.55 compared
221 to the Control group (Fig. 2).

222 Chao1 and Shannon indexes were used to express the alpha diversity of
223 microbiology communities in the cecum (Fig. 3A). *C. butyricum*, sodium butyrate,
224 and oxytetracycline supplementation altered the community's species diversity as
225 compared to the Control group (Fig. 3A). The principal coordinates analysis (PCoA)
226 based on uniFrac distance was used to assess the community structure differences of
227 four groups. The findings revealed that four diets clearly separated the microbiota
228 (Fig. 3B). According to the Venn diagram, there were 1004 universal OTUs shared by
229 all four groups, as well as 2689, 2516, 3911, and 3442 unique OTUs in the Control,
230 CB, SB, and Antibiotic groups, respectively (Fig. 3C). Furthermore, linear
231 discriminant analysis (LDA) showed that *Tannerellaceae* and *Parabacteroides* were
232 considerably more abundant in the CB group (Fig. 3D), while the addition of SB
233 increased the abundances of *Campylobacter*, *sulfurimonas*, and *Paludibacter* (Fig.
234 3D).

235 At the phylum level, the relative abundance of microbial communities revealed
236 that *Firmicutes* and *Bacteroidota* were the most abundant orders (Fig. 4A). Among
237 these, the *Firmicutes/Bacteroidota* ratio was lower in the CB group, while it was
238 close to the Control group in the other two groups (SB, Antibiotic) (Fig. 4A). At the
239 genus level, *Rikenellaceae*, *Alistipes*, and *Coprobacter* were the most predominant

240 orders in the Control group (Fig. 4B). The findings showed that the addition of *C.*
241 *butyricum* produced the most significant change in microbial structure among the
242 three treatments, with the abundance of *Rikenellaceae* increasing (Fig. 4B).
243 Furthermore, the abundance of *Alistipes*, *phascolarctobacterium* and *Coprobacter* was
244 decreased in the CB, SB, and Antibiotic groups (Fig. 4B).

245

246 ***C. butyricum* promotes SCFAs production more effectively than sodium butyrate**

247 Data revealed significant changes ($p < 0.05$) in concentrations of all identified SCFAs
248 (acetic acid, propionic acid, and butyric acid) in broiler ileum chyme across three
249 supplementation groups (CB, SB, Antibiotic) compared to the Control group (Fig. 5).
250 In particular, the concentration of acetic acid was increased from 40.85 $\mu\text{g/g}$ to 283.42
251 $\mu\text{g/g}$ in the SB group at 21 d, which showed the most significant differences (Fig. 5).
252 Besides, data revealed that sodium butyrate supplementation promoted SCFAs
253 production better than *C. butyricum* (Fig. 5).

254 It was clear that concentrations of SCFAs in cecal chyme were considerably
255 higher than those in the ileum (Fig. 5 and Fig. 6). Moreover, compared with the basal
256 diet group, the supplementation of *C. butyricum*, sodium butyrate, or oxytetracycline
257 all increased the concentrations of SCFAs to a similar extent in the cecum of 21 days
258 and 42 days old broilers ($p < 0.05$, Fig. 6).

259

260 ***C. butyricum* improves anti-inflammatory response more than sodium butyrate**

261 Broilers fed with CB diet or antibiotic diet exhibited lower concentrations of TAK1
262 and NF-kB ($p < 0.05$) in jejunal mucosa than those fed with basal diet or SB diet at 21
263 days of age (Fig. 7A). Among these, the addition of *C. butyricum* decreased the
264 expression level of TAK1 by 2.23 times (Fig. 7A). At 42 d, the three treatments (CB,
265 SB, Antibiotic) showed various degrees of inhibitory effects on the expression of two
266 genes (Fig. 7A). It's worth mentioning that SB-supplementation decreased the
267 expression of TAK1 and NF-kB at 42 d, while there was no expression inhibition on
268 21-day old broilers (Fig. 7A). The inhibitory effect of CB on the expression of two
269 genes was more significant than SB (Fig. 7A).

270 As for inflammatory factors, the supplementation of oxytetracycline did not
271 inhibit the expression of inflammatory factors (Fig. 7B). CB diet decreased the
272 expression levels of IL-1 β and IL-6 during 1-21 d ($p < 0.05$, Fig. 7B) and that of IL-
273 1 β , IL-6, and TNF- α during 1-42 d ($p < 0.05$, Fig. 7B). Especially, the expression of
274 IL-6 decreased by 2.37 times when compared with the Control group at 42d (Fig. 7B).
275 For the SB-supplemented group, other than the expression of IL-6 at 21d which was
276 increased, the rest were all decreased (Fig. 7B). Although both *C. butyricum* and
277 sodium butyrate were helpful to the broilers, the benefits of *C. butyricum* were more
278 apparent (Fig. 7B).

279

280 Discussion

281 According to the findings (Table 4), there were no significant differences ($p > 0.05$) in
282 broiler growth indicators between the CB or SB groups and the Antibiotic group. The

283 probiotic effect of *C. butyricum* and sodium butyrate on growth performance is
284 consistent with earlier findings (20), suggesting that these two butyrate supplements
285 may be used instead of growth-promoting antibiotics. Notably, the feed to gain ratio
286 (F/G) in the CB group significantly decreased ($p < 0.05$) throughout the experimental
287 period (1-42 d), although body weight gain (BWG) remained constant (Table 4). We
288 hypothesized that supplemented strain's vector reduced feed intake (FI), however,
289 butyric acid generated by *C. butyricum* supplied approximately 10-30% of the energy
290 needs for broilers (21), and improved food digestibility by lowering intestinal pH and
291 inhibiting pathogenic bacteria (22). There have also been reports that a *C. butyricum*
292 or sodium butyrate diet has no impact on animal growth performance (23), which may
293 be related to the effective dosage, diet structure, animal health, and even
294 environmental factors.

295 Sodium butyrate significantly increased FI and BWG as compared to the *C.*
296 *butyricum* group ($p < 0.05$, Table 4). Sodium butyrate, whose probiotic function is
297 mostly dictated by dosage, may stimulate growth stably if taken in adequate
298 quantities. The probiotic effect of *C. butyricum*, on the other hand, will be affected by
299 a variety of factors, including viable count and intestine physiological state.
300 Furthermore, strain in the gut consumes enteral nutrients, reducing growth
301 performance. According to these findings, sodium butyrate is a more stable butyrate
302 supplementation for broiler growth performance than *C. butyricum*.

303 Intestinal health is defined as having a fully functional intestinal structure,
304 intestinal mucosal immune balance, and intestinal microbial balance. In this study, the

305 intestinal morphological structure was damaged by antibiotics as shown by decreased
306 V/C at different periods (Fig. 1 and Table 5). However, *C. butyricum* and sodium
307 butyrate diets both significantly improved the villus height (V), crypt depth (C), and
308 V/C of jejunum, ileum, and cecum ($p < 0.05$, Table 5), preserving the normal
309 morphology of the intestinal epithelial cell (Fig. 1), which is consistent with the
310 previous findings (24). Furthermore, when compared to *C. butyricum*, the findings
311 showed that sodium butyrate was more beneficial for maintaining intact intestinal
312 structure (Table 5). We hypothesized that since sodium butyrate was in close contact
313 with the intestinal tract, it would help to restore the intestinal barrier more rapidly.

314 The major tight junction proteins in the animal gut, Occludin and ZO-1, are
315 important markers for assessing intestinal permeability and integrity (25). Li et al
316 found that *C. butyricum* could significantly increase the expression of Occludin, ZO-
317 1, and Claudin-3 in pigs infected with *Escherichia coli* K88 (15). In this study, *C.*
318 *butyricum* and sodium butyrate both increased the expression of Occludin and ZO-1
319 in jejunal epithelial cells (Fig. 2), resulting in decreased permeability of intestinal
320 epithelial cells, which prevented the passage of toxins and pathogens and decreased
321 disease occurrence. Simultaneously, *C. butyricum* exhibited a more pronounced
322 expression-promoting effect than sodium butyrate (Fig. 2). We hypothesized that *C.*
323 *butyricum* improved intestinal barrier function more continuously through both live
324 bacteria and its metabolites.

325 In this study, a sodium butyrate diet increased the species diversity of the cecal
326 community, as reflected by the Chao1 index and Venn diagram (Fig. 3A and C).

327 *Paludibacter*, whose abundance increased in the SB group, has been identified as a
328 propionate-producing bacteria (26) and may help to enhance the species diversity of
329 the cecal community via the probiotic function of propionate. However, compared to
330 the Control group, the species diversity of the sample in the CB group was decreased
331 (Fig. 3A and C), which differs from the study in *C. butyricum*-supplemented laying
332 hens (27). Furthermore, we hypothesized that *C. butyricum* might be viable in broiler
333 guts but does not colonize, therefore *C. butyricum* was not included in the list of
334 dominating species in the CB group (Fig. 3D).

335 There are many and complex microbiotas in the poultry intestine, the
336 composition, and diversity of which are affected by a variety of factors (28).
337 Meanwhile, the intestinal microbiota has an impact on host health (29). Wu et al.
338 found that 800 mg/kg sodium butyrate significantly decreased the relative abundance
339 of *Enterobacteriaceae* but increased that of *Lachnospiraceae* and *Rikenellaceae* in
340 broilers cecum (30). *Rikenellaceae*, the main component at the genus level in this
341 study, was similarly increased in supplemented groups (CB, SB) compared to the
342 Control group (Fig. 4). Because of its high carbohydrate fermentation capacity, this
343 species could generate butyrate and therefore exert a probiotic function on the host
344 (31). When butyrate supplementation was administered, other dominating bacteria,
345 such as *Clostridial* and *Lactobacillus*, which could both generate SCFAs increased
346 (Fig. 4). Furthermore, the detection of SCFAs concentrations revealed that SCFAs in
347 the CB and SB groups were much higher than that in the Control group (Fig. 5 and
348 Fig. 6), supporting the conclusion that SCFAs-producing bacteria were the dominant

349 intestinal microbiota and significantly contributed to host health.

350 TAK1 is an IKK kinase involved in the NF- κ B signaling pathway (32). NF- κ B is
351 an important transcription factor that promotes the expression of a variety of
352 inflammatory and immune-related genes (33). TAK1 and NF- κ B expression levels
353 were significantly lower in the treatment groups (CB, SB, Antibiotic) than that in the
354 Control group ($p < 0.05$) (Fig. 7A), suggesting that *C. butyricum*, sodium butyrate,
355 and oxytetracycline may all inhibit the activation of the NF- κ B pathway to reduce
356 inflammation. Besides, CB supplementation outperformed the SB diet in terms of
357 inhibiting the inflammatory response (Fig. 7A).

358 TNF- α , IL-1 β , and IL-6 are the three main inflammatory cytokines that reflect
359 the host's inflammatory state (34). Chen et al. found that 0.4% *C. butyricum*
360 significantly decreased the expression of TNF- α and increased the expression of the
361 anti-inflammatory cytokine IL-10 in weaned piglet ileum mucosa (35). Ni et al.
362 reported that butyric acid up-regulated the production of IL-10 and inhibited the
363 production of TNF- α , IL-1 β , and NO (36). In this study, *C. butyricum* and sodium
364 butyrate both decreased TNF- α , IL-1 β , and IL-6 expression (Fig. 7B), alleviating
365 inflammation and promoting intestinal homeostasis in broilers. Furthermore, *C.*
366 *butyricum* decreased the expression of inflammatory cytokines more than sodium
367 butyrate in most cases (Fig. 7B), suggesting that *C. butyricum* has more apparent anti-
368 inflammatory benefits than sodium butyrate, which was consistent with the results on
369 the expression of signaling pathway-related genes (Fig. 7A). We hypothesized that the
370 numerous SCFAs generated by *C. butyricum*, including not only butyric acid but also

371 acetic acid and propionic acid would have additive effects on the inhabitation of
372 expression of inflammation related genes, enhancing the host's inflammatory
373 regulation.

374

375 **Conclusion**

376 *C. butyricum* or sodium butyrate supplementation in the basal diet showed beneficial
377 effects on broiler's growth performance, intestinal health, and anti-inflammatory
378 response. However, these two supplements have varying degrees of probiotic
379 functions in various aspects. Specifically, sodium butyrate promoted broiler growth
380 and maintained intact intestinal structure more effectively, while *C. butyricum* is more
381 beneficial for production of tight junction protein and SCFAs, as well as anti-
382 inflammatory response. Based on the functional comparison of these two butyrate
383 supplements, we believe that our study will offer references for appropriate selection
384 and support the growth of the broiler breeding industry.

385

386 **Abbreviations**

387 CB: *Clostridium butyricum*; SB: Sodium butyrate; SCFAs: Short-chain fatty acids; FI:
388 Feed intake; BWG: Body weight gain; V: Villi height; C: Crypt depth; OTUs:
389 Operational taxonomic units; GC-MS: Gas chromatography-mass spectrometry; EI:
390 Electron bombardment ionization; ZO-1: Zonula occludens-1; TAK1: TGF- β activated
391 kinase-1; NF-kB: Nuclear factor kappa B; IL-1 β : Interleukin-1 β ; IL-6: Interleukin-6;
392 TNF- α : Tumor necrosis factor- α ; PCoA: Principal coordinates analysis; LDA: Linear

393 discriminant analysis; IKK: Inhibitor of nuclear factor kappa B kinase; IL-10:
394 Interleukin-10.

395

396 **Declarations**

397 **Ethics approval and consent to participate**

398 All experiments were performed in accordance with the ethical standards of
399 Huazhong Agriculture University's Laboratory Animal Center (HZAUCH-2019-008).

400

401 **Consent for publication**

402 Not applicable.

403

404 **Availability of data and materials**

405 The datasets used and/or analysed during the current study are available from the
406 corresponding author on reasonable request.

407

408 **Competing interests**

409 The authors declare that they have no competing interests.

410

411 **Funding**

412 This work was supported by the Key Research and Development Project of Hubei
413 Province (No. 2020BBA054)

414

415 **Authors' contributions**

416 LL and HL carried out the animal experiments and data analysis, and drafted the
417 manuscript. WZ and YZ participated in the animal trial. YL and NP helped with study
418 design. SZ designed the study and revised the manuscript. All authors read and
419 approved the final manuscript.

420

421 **Acknowledgments**

422 Not applicable.

423

424 **Authors' information**

425 Not applicable.

426

427 **References**

- 428 1. Fan P, Li L, Rezaei A, Eslamfam S, Che D, Ma X. Metabolites of dietary protein
429 and peptides by intestinal microbes and their impacts on gut. *Curr Protein Pept*
430 *Sci.* 2015;16:646-54.
- 431 2. Koh A, De Vadder F, Kovatcheva-Datchary P, Backhed F. From dietary fiber to
432 host physiology: short-chain fatty acids as key bacterial metabolites. *Cell.*
433 2016;165:1332-1345.
- 434 3. Brahe LK, Astrup A, Larsen LH. Is butyrate the link between diet, intestinal
435 microbiota and obesity-related metabolic diseases? *Obes Rev.* 2013;14:950-9.
- 436 4. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role


- 437 of short-chain fatty acids in health and disease. *Adv Immunol.* 2014;121:91-119.
- 438 5. Guilloteau P, Martin L, Eeckhaut V, Ducatelle R, Zabielski R, Van Immerseel F.
439 From the gut to the peripheral tissues: the multiple effects of butyrate. *Nutr Res*
440 *Rev.* 2010;23:366-84.
- 441 6. Chen J, Li Y, Tian Y, Huang C, Li D, Zhong Q, et al. Interaction between
442 microbes and host intestinal health: modulation by dietary nutrients and gut-
443 brain-endocrine-immune axis. *Curr Protein Pept Sci.* 2015;16:592-603.
- 444 7. Jacobi SK, Odle J. Nutritional factors influencing intestinal health of the neonate.
445 *Adv Nutr.* 2012;3:687-96.
- 446 8. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. The
447 role of butyrate on colonic function. *Aliment Pharmacol Ther.* 2008;27:104-19.
- 448 9. Luo H, Yang R, Zhao Y, Wang Z, Liu Z, Huang M, et al. Recent advances and
449 strategies in process and strain engineering for the production of butyric acid by
450 microbial fermentation. *Bioresour Technol.* 2018;253:343-354.
- 451 10. Jiang L, Fu H, Yang HK, Xu W, Wang J, Yang ST. Butyric acid: applications and
452 recent advances in its bioproduction. *Biotechnol Adv.* 2018;36:2101-2117.
- 453 11. Cassir N, Benamar S, La Scola B. *Clostridium butyricum*: from beneficial to a
454 new emerging pathogen. *Clin Microbiol Infect.* 2016;22:37-45.
- 455 12. Molnar A, Such N, Farkas V, Pal L, Menyhart L, Wagner L, et al. Effects of
456 wheat bran and *Clostridium butyricum* supplementation on cecal microbiota,
457 short-chain fatty acid concentration, pH and histomorphometry in broiler
458 chickens. *Animals (Basel).* 2020;10:2230.

- 459 13. Huang T, Peng XY, Gao B, Wei QL, Xiang R, Yuan MG, et al. The Effect of
460 *Clostridium butyricum* on gut microbiota, immune response and intestinal barrier
461 function during the development of necrotic enteritis in chickens. Front
462 Microbiol. 2019;10:2309.
- 463 14. Takahashi M, McCartney E, Knox A, Francesch M, Oka K, Wada K, et al. Effects
464 of the butyric acid-producing strain *Clostridium butyricum* MIYAIRI 588 on
465 broiler and piglet zootechnical performance and prevention of necrotic enteritis.
466 Anim Sci J. 2018;89:895-905.
- 467 15. Li HH, Li YP, Zhu Q, Qiao JY, Wang WJ. Dietary supplementation with
468 *Clostridium butyricum* helps to improve the intestinal barrier function of weaned
469 piglets challenged with enterotoxigenic *Escherichia coli* K88. J Appl Microbiol.
470 2018;125:964-975.
- 471 16. Piva A, Morlacchini M, Casadei G, Gatta PP, Biagi G, Prandini A. Sodium
472 butyrate improves growth performance of weaned piglets during the first period
473 after weaning. Ital J Anim Sci. 2016;1:35-41.
- 474 17. Hu Z, Guo Y. Effects of dietary sodium butyrate supplementation on the intestinal
475 morphological structure, absorptive function and gut flora in chickens. Anim
476 Feed Sci Tech. 2007;132:240-249.
- 477 18. Smulikowska S, Czerwinski J, Mieczkowska A, Jankowiak J. The effect of fat-
478 coated organic acid salts and a feed enzyme on growth performance, nutrient
479 utilization, microflora activity, and morphology of the small intestine in broiler
480 chickens. J Anim Feed Sci. 2009;18:478-489.

- 481 19. Zhou D, Pan Q, Xin FZ, Zhang RN, He CX, Chen GY, et al. Sodium butyrate
482 attenuates high-fat diet-induced steatohepatitis in mice by improving gut
483 microbiota and gastrointestinal barrier. *World J Gastroenterol.* 2017;23:60-75.
- 484 20. Lan RX, Li SQ, Zhao Z, An LL. Sodium butyrate as an effective feed additive to
485 improve growth performance and gastrointestinal development in broilers. *Vet*
486 *Med Sci.* 2020;6:491-499.
- 487 21. Bergman EN. Energy contributions of volatile fatty acids from the
488 gastrointestinal tract in various species. *Physiol Rev.* 1990;70:567-90.
- 489 22. Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines
490 and NF-kappaB activation in ulcerative colitis. *World J Gastroenterol.*
491 2010;16:4145-51.
- 492 23. Zhang B, Yang X, Guo Y, Long F. Effects of dietary lipids and *Clostridium*
493 *butyricum* on the performance and the digestive tract of broiler chickens. *Arch*
494 *Anim Nutr.* 2011;65:329-339.
- 495 24. Sikandar A, Zaneb H, Younus M, Masood S, Aslam A, Khattak F, et al. Effect of
496 sodium butyrate on performance, immune status, microarchitecture of small
497 intestinal mucosa and lymphoid organs in broiler chickens. *Asian Austral J Anim.*
498 2017;30:690-699.
- 499 25. Zong QF, Huang YJ, Wu LS, Wu ZC, Wu SL, Bao WB. Effects of porcine
500 epidemic diarrhea virus infection on tight junction protein gene expression and
501 morphology of the intestinal mucosa in pigs. *Pol J Vet Sci.* 2019;22:345-353.
- 502 26. Qiu YL, Kuang XZ, Shi XS, Yuan XZ, Guo RB. *Paludibacter jiangxiensis sp.*


- 503 *nov.*, a strictly anaerobic, propionate-producing bacterium isolated from rice
504 paddy field. Arch Microbiol. 2014;196:149-55.
- 505 27. Wang WW, Wang J, Zhang HJ, Wu SG, Qi GH. Supplemental *Clostridium*
506 *butyricum* modulates lipid metabolism through shaping gut microbiota and bile
507 acid profile of aged laying hens. Front Microbiol. 2020;11:600.
- 508 28. Stanley D, Geier MS, Denman SE, Haring VR, Crowley TM, Hughes RJ, et al.
509 Identification of chicken intestinal microbiota correlated with the efficiency of
510 energy extraction from feed. Vet Microbiol. 2013;164:85-92.
- 511 29. Zeng B, Li G, Yuan J, Li W, Tang H, Wei H. Effects of age and strain on the
512 microbiota colonization in an infant human flora-associated mouse model. Curr
513 Microbiol. 2013;67:313-21.
- 514 30. Wu W, Xiao Z, An W, Dong Y, Zhang B. Dietary sodium butyrate improves
515 intestinal development and function by modulating the microbial community in
516 broilers. Plos One. 2018;13:e0197762.
- 517 31. Vander Wyst KB, Ortega-Santos CP, Toffoli SN, Lahti CE, Whisner CM. Diet,
518 adiposity, and the gut microbiota from infancy to adolescence: a systematic
519 review. Obes Rev. 2021;22:e13175.
- 520 32. Adhikari A, Xu M, Chen ZJ. Ubiquitin-mediated activation of TAK1 and IKK.
521 Oncogene. 2007; 26:3214-26.
- 522 33. Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-kappaB: a blossoming of
523 relevance to human pathobiology. Cell. 2017;168:37-57.
- 524 34. Alvarez AM, DeOcesano-Pereira C, Teixeira C, Moreira V. IL-1beta and TNF-

- 525 alpha modulation of proliferated and committed myoblasts: IL-6 and COX-2-
526 derived prostaglandins as key actors in the mechanisms involved. *Cells*.
527 2020;9:2005.
- 528 35. Chen L, Li S, Zheng J, Li W, Jiang X, Zhao X, et al. Effects of dietary
529 *Clostridium butyricum* supplementation on growth performance, intestinal
530 development, and immune response of weaned piglets challenged with
531 lipopolysaccharide. *J Anim Sci Biotechnol*. 2018;9:62.
- 532 36. Ni YF, Wang J, Yan XL, Tian F, Zhao JB, Wang YJ, et al. Histone deacetylase
533 inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in
534 mice. *Respir Res*. 2010;11:33.



535


536 **Fig 1. Intestinal tissue morphology.** Samples of the jejunum, ileum, and cecum
 537 (approximately 1-2 cm obtained from the midpoint) at 21 d and 42 d were fixed. Villi
 538 and goblet cells were observed from eosin-methylene blue-stained sections of samples
 539 by optical microscopy at 40 ×.



540

541 **Fig 2. Tight junction protein expression in broiler jejunum.** Significant differences

542 are shown by bars labeled with various letters.



543

544 **Fig 3. Effects of different feed additives on intestinal microbial community**


545 **structure in the cecum. (A)** Alpha diversity was assessed by Chao1 and Shannon

546 indexes. **(B)** Principal coordinates analysis (PCoA) based on UniFrac distance was

547 used to represent the community structural differences of four groups. **(C)** OUT Venn

548 diagram. **(D)** Linear discriminant analysis (LDA) scores for various taxa abundances.


549 Data were presented as mean \pm SD.



550

551 **Fig 4. Taxonomic differences in broiler caeca microbial community. (A) Phylum**

552 **levels. (B) Genus levels. Data were presented as mean \pm SD.**




553

554 **Fig 5. SCFAs concentrations in ileum chyme of broilers. (A) Acetic acid. (B)**

555 Propanoic acid. (C) Butyric acid. SCFAs concentrations were expressed in microgram

556 per gram of chyme sample (µg/g). Significant differences are shown by bars labeled

557 with various letters.




558

559 **Fig 6. SCFA concentrations in broiler cecum chyme. (A) Acetic acid. (B)**

560 Propanoic acid. (C) Butyric acid. SCFAs concentrations were expressed as

561 micrograms per gram of chyme sample (µg/g). Significant differences are shown by

562 bars labeled with various letters.



563

564 **Fig 7. Expression of inflammatory and immune-related genes in broiler jejunal**

565 **mucosa. (A) Signaling pathway-related protein. (B) Inflammatory cytokines.**

566 Significant differences are shown by bars labeled with various letters.

567 **Table 1. Groups and diets**

Groups	Diets
Control	Basal diet
CB	Basal diet + <i>C. butyricum</i> (1.0×10^9 CFU/t)
SB	Basal diet + sodium butyrate (500 g/t)
Antibiotic	Basal diet + oxytetracycline (200 g/t)

568

569 **Table 2. Nutrient levels and composition of basic diet**

Item (% unless noted)	Starter (1-21 d)	Grower (22-42 d)
Ingredients		
Corn (7.8%, crude protein)	530	540
Soybean meal (43%, crude protein)	360	342.50
Rapeseed meal	0	20
Fish powder (68%)	30	0
Soybean oil	40	60
Limestone	12	13
CaHPO ₄	14	13
Lysine (70%)	4	2.80
Methionine	2	1.50
Salt	3	3
Choline Chloride (50%)	1	1
Rice bran	0.80	0
Multivitamin*	2	2
Multimineral [†]	1.20	1.20
Total	1,000	1,000
Calculated nutrient levels		
Metabolic energy (Mcal/kg)	3,030	3,150
Crude protein	22	20
TP	0.69	0.60
AP	0.45	0.35
Ca	1	0.88

Lys	1.45	1.20
Met	0.55	0.45
Met+Cys	0.88	0.78
Thr	0.92	0.84
Trp	0.28	0.25
Arg	1.20	1.12

570 *Supplied per kilogram of diet: retinyl acetate 5,000-10,000 KIU; vitamin D3 2,000-
571 5,000 KIU; DL- α -tocopheryl acetate \geq 25,000 mg; menadione \geq 2,400 mg; thiamine
572 nitrate \geq 2,000 mg; riboflavin \geq 6,000 mg; vitamin B6 \geq 3,500 mg; cyanocobalamin \geq
573 12 mg; nicotinamide \geq 30,000 mg; D-biotin \geq 75 mg; D-calcium pantothenate \geq 8,000
574 mg; folic acid \geq 950 mg.

575 †Supplied per kilogram of diet: copper 6,000-18,000 mg; iron 30,000-150,000 mg;
576 manganese 60,000-125,000 mg; zinc 50,000-100,000 mg; iodine 400-900 mg;
577 selenium 150-300 mg.

578 **Table 3. Primers used in this study**

Primers	Sequence (5'-3')
ZO-1-F	TCGGGTTGTGGACACGCTAT
ZO-1-R	TTCATAGGCAGGGAACTTTGTCT
Occludin-F	G TTCCTCATCGTCATCCTGCTC
Occludin-R	CGTTCTTCACCCACTCCTCCAC
TAK1-F	ATGATAATGATTGTCCTACTGCCCC
TAK1-R	GGCAGGCTCAAATGGTAGGC
NF- κ B-F	ATGCTCACAGCTTGGTGGGTAA
NF- κ B-R	TCATGCGTGTTTCCAGAGTTTC
IL-1 β -F	ATGACCAAACCTGCTGCGGAG
IL-1 β -R	AAGGACTGTGAGCGGGTGTAG
IL-6-F	GGTGATAAATCCCGATGAAGTGG
IL-6-R	AGGCACTGAAACTCCTGGTCTT
TNF- α -F	GGAATGAACCCTCCGCAGTA
TNF- α -R	GCAACAACCAGCTATGCACCC
β -actin-F	CTGACTGACCGCGTTACTCC
β -actin-R	TTGCACATAACCGGAGCCATT
341F	CCTACGGGAGGCAGCAG
534R	TAGATTACCGCGGCTGCT

579

580 **Table 4. Effects of diet on the growth of broilers**

	Control	CB	SB	Antibiotic
1-21 d				
FI	41.09 ± 0.97	40.89 ± 0.91	41.54 ± 0.79	40.95 ± 1.06
BWG	27.94 ± 0.69 ^b	28.82 ± 0.84 ^{ab}	29.37 ± 0.98 ^a	28.78 ± 0.61 ^{ab}
F/G	1.47 ± 0.06	1.42 ± 0.06	1.42 ± 0.04	1.42 ± 0.04
22-42 d				
FI	115.68 ± 5.95 ^a	106.57 ± 7.91 ^b	118.80 ± 6.32 ^a	114.85 ± 5.77 ^a
BWG	56.31 ± 2.75 ^b	56.16 ± 3.30 ^b	62.16 ± 5.27 ^a	60.45 ± 3.76 ^{ab}
F/G	2.05 ± 0.04 ^a	1.90 ± 0.08 ^b	1.92 ± 0.07 ^b	1.90 ± 0.04 ^b
1-42 d				
FI	78.38 ± 3.19 ^a	73.73 ± 3.81 ^b	80.17 ± 3.52 ^a	77.90 ± 3.31 ^a
BWG	42.13 ± 1.32 ^b	42.49 ± 1.96 ^b	45.76 ± 2.71 ^a	44.61 ± 2.16 ^{ab}
F/G	1.86 ± 0.04 ^a	1.74 ± 0.05 ^b	1.75 ± 0.04 ^b	1.75 ± 0.04 ^b

581 FI, feed intake (g); BWG, body weight gain (g); F/G, feed to gain ratio.

582 **Table 5. Effects of diet on structure of intestinal villi in broilers.**

		Control	CB	SB	Antibiotics
21 d					
	V	711.73 ± 124.66 ^b	987.79 ± 124.66 ^a	985.14 ± 221.50 ^a	628.08 ± 62.30 ^b
Jejunum	C	151.82 ± 46.53 ^{ab}	129.24 ± 19.89 ^b	120.60 ± 33.68 ^b	173.74 ± 27.38 ^a
	V/C	4.88 ± 0.91 ^b	7.62 ± 1.06 ^a	8.41 ± 1.77 ^a	3.68 ± 0.71 ^b
	V	549.93 ± 63.83 ^b	504.15 ± 26.07 ^b	705.65 ± 132.81 ^a	523.35 ± 38.44 ^b
Ileum	C	127.23 ± 12.19 ^a	76.58 ± 9.15 ^c	100.37 ± 11.83 ^b	132.22 ± 12.22 ^a
	V/C	4.07 ± 0.24 ^b	6.70 ± 1.15 ^a	7.08 ± 1.37 ^a	4.00 ± 0.58 ^b
	V	143.95 ± 25.52 ^b	166.58 ± 27.15 ^{ab}	187.70 ± 17.85 ^a	140.79 ± 11.51 ^b
Cecum	C	128.07 ± 20.29	115.80 ± 15.16	111.82 ± 28.91	142.61 ± 29.28
	V/C	1.13 ± 0.20 ^{bc}	1.45 ± 0.27 ^{ab}	1.74 ± 0.34 ^a	1.03 ± 0.27 ^c
42 d					
	V	1,015.09 ± 176.38 ^{bc}	1,138.61 ± 157.01 ^{ab}	1,201.12 ± 92.46 ^a	903.92 ± 102.50 ^c
Jejunum	C	185.74 ± 17.82 ^b	279.79 ± 38.46 ^a	184.77 ± 58.36 ^b	246.79 ± 54.33 ^a
	V/C	5.43 ± 0.59 ^b	4.11 ± 0.67 ^c	6.93 ± 1.63 ^a	3.79 ± 0.82 ^c
	V	754.30 ± 119.87 ^b	936.03 ± 129.26 ^a	795.69 ± 113.05 ^b	672.43 ± 78.85 ^b
Ileum	C	142.10 ± 27.63 ^{ab}	145.51 ± 31.00 ^{ab}	120.57 ± 29.15 ^b	173.00 ± 31.22 ^a
	V/C	5.39 ± 0.83 ^b	6.58 ± 1.29 ^a	6.73 ± 1.18 ^a	4.07 ± 1.10 ^c
	V	152.05 ± 36.18 ^b	195.83 ± 10.99 ^a	193.05 ± 18.61 ^a	147.59 ± 19.09 ^b
Cecum	C	165.19 ± 40.80 ^{ab}	135.46 ± 27.13 ^{bc}	111.43 ± 13.46 ^c	174.54 ± 33.77 ^a
	V/C	0.93 ± 0.13 ^b	1.50 ± 0.35 ^a	1.75 ± 0.24 ^a	0.88 ± 0.23 ^b

583 V, villus height (μm); C, crypt depth (μm); V/C, villus height to crypt depth.